OESO-SEMPIRE 17th World Conference | Esophagus 2026 | Versailles | June 14-17, 2026

Session 7: Laryngopharyngeal Reflux Disease (LPRD): Cutting Through the Noise

Monday, June 15, 2:00 – 3:30 pm
Auditorium Lulli

Chairs: Frank Zerbib (France) – Nikki Johnston (USA)

  1. What does the San Diego Consensus change in clinic? – Thomas L. Carroll (USA)
  2. What is the value in establishing a new ICD-10 CM code for LPRD? Alexandra Vandenberg (USA)
  3. Is GMA biomarker subtyping the key to understanding and treating GERD/LPR? – Mark Noar (USA)
  4. Alginate, H2RA, PPI, neuromodulation, or lifestyle first – what’s your first script? – Jacqui Allen (New Zealand)
  5. What is the role of sedated POEM procedures for UES issues? – Pavan Mallur (USA) 
  6. What is your oropharyngeal dysphagia management protocol for LPR? – Derrick Randall (Canada) 
  7. What are the pathogenic elements of refluxate in LPRD: acid, pepsin, bile, and beyond? – Tina Samuels (USA) 
  8. What is the status of pepsin inhibitors for LPR? – Nikki Johnston (USA)
  9. What is the current understanding of the role of reflux in promoting laryngopharngeal cancer? – Jérôme R. Lechien (Belgium) 
  10. Which surgical or endoscopic options work for extra-esophageal disease? – Stefano Siboni (Italy)

Structured Debate:

Motion: “This house supports the San Diego Consensus Statement as the governing guideline for LPRD.”

  • FOR: Walter W. Chan (USA) – (defending the Consensus statements & pathways).
  • AGAINST: Mark Noar (USA) – (challenging external validity, symptom-first pathways, and laryngology-specific nuances).

Case-Based Panel + Audience Interaction:

All panelists on stage for questions and discussion: Jonathan Bock (USA) – Jacqui Allen (New Zealand) – Mark Noar (USA) – Edoardo Savarino (Italy) – Serhat Bor (Turkey) – Stefano Siboni (Italy) – Jérôme R. Lechien (Belgium) – Thomas L. Carroll (USA)

  1. Chronic cough with normal acid exposure but high non-acid events: “Does therapy change?”
    Panel lead: Jonathan Bock (USA) 
  2. Mucosal protection: formulations and their place in the management of GERD and LPR.
    Panel lead: Serhat Bor (Turkey)
  3. Refractory LPS after maximal PPI & alginate: “Is it time for surgery or is it not reflux?”
    Panel lead: Stefano Siboni (Italy)